DPT Laboratories has received notification from the FDA on February 19, 2013, signaling the completion of DPT’s corrective actions taken at its Lakewood, NJ facility in response to the warning letter received on August 27, 2012. The letter also communicated that the Lakewood site is compliant with FDA regulations.
“We are pleased to have this issue behind us and appreciate the confidence our new and existing customers demonstrated in us during this time,” said Eugene Ciolfi, DPT vice president and general manager. “I am excited and optimistic about the opportunities ahead of us in 2013.”
“This resolution has strengthened DPT,” said Paul Johnson, DPT Group president and chief operating officer. “Our commitment to quality and continuous improvement will remain a priority as we continue building a world-class business.”